RATIONALE: Unilateral manifestation of lymphedema during everolimus therapy has been described only rarely, mostly in transplant recipients. PATIENT CONCERNS: We report the first case of a patient who developed unilateral abdominal lymphedema, during a short period of everolimus treatment for renal cancer. DIAGNOSIS: The abdominal asymmetry occurred only on the right side of the abdomen, neither ultrasound nor CT scan detected ascites but showed enlargement of the abdominal wall. The Naranjo Adverse Drug Reaction Probability scale was evaluated, in this case, a score of 6 indicated a probable adverse reaction to everolimus. INTERVENTIONS: Discontinuation of everolimus therapy led to immediate alleviation and reduction of the lymphedema, with worsening once again after initiating retreatment with everolimus at a reduced dose. OUTCOMES: The patient's lymphedema recovered after discontinuation of everolimus. LESSONS: This rare case demonstrates the importance of the selection of mammalian target of rapamycin inhibitors using caution, especially for patients with a high risk of developing lymphedema.

Clinical Trial Unit Masaryk Memorial Cancer Institute

Department of Cancer Comprehensive Care

Department of Cancer Comprehensive Care Masaryk Memorial Cancer Institute Faculty of Medicine Masaryk University

Department of Medical Ethics Faculty of Medicine Masaryk University

Department of Pharmacology Faculty of Medicine Masaryk University Brno Czech Republic

Department of Radiation Oncology Masaryk Memorial Cancer Institute Faculty of Medicine Masaryk University

Department of Radiology Masaryk Memorial Cancer Institute

See more in PubMed

Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006;12:122–7. PubMed

Tanaka C, O’Reilly T, Kovarik JM, et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008;26:1596–602. PubMed

Boulay A, Zumstein-Mecker S, Stephan C, et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004;64:252–61. PubMed

Huber S, Bruns CJ, Schmid G, et al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int 2007;71:771–7. PubMed

Hille U, Soergel P, Makowski L, et al. Lymphedema of the breast as a symptom of internal diseases or side effect of mTOR inhibitors. Lymphat Res Biol 2012;10:63–73. PubMed

Dincel N, Bulut IK, Sezer TÖ, et al. Clinical everolimus experience in pediatric renal transplant patients. Transplant Proc 2013;45:913–6. PubMed

Ersoy A, Koca N. Everolimus-induced lymphedema in a renal transplant recipient: a case report. Exp Clin Transplant 2012;10:296–8. PubMed

Rico J, Cruzado JM, Bestard O, et al. Subclinical rejection and sirolimus associated edema in renal allograft recipients. Transpl Int 2007;20:636–9. PubMed

De Bartolomeis C, Collini A, Rumberger B, et al. Generalized lymphedema in a sirolimus-treated renal transplant patient. Clin Transplant 2008;22:254–7. PubMed

Moro JA, Almenar L, Martínez-Dolz L, et al. mTOR inhibitors and unilateral edema. Rev Esp Cardiol 2008;61:987–8. PubMed

Naranjo CA, Sellers EM, Busto U, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–45. PubMed

Olsson AK, Dimberg A, Kreuger J, et al. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006;7:359–71. PubMed

Karkkainen MJ, Ferrell RE, Lawrence EC, et al. Missense mutations interfere with VEGFR-3 signalling in primary lymphedema. Nat Genet 2000;25:153–9. PubMed

Mäkinen T, Jussila L, Veikkola T, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 2001;7:199–205. PubMed

Pascual J, Marcén R, Ortuño J. Clinical experience with everolimus (certican): optimizing dose and tolerability. Transplantation 2005;79:S80–4. PubMed

Desai N, Heenan S, Mortimer PS. Sirolimus-associated lymphedema: eight new cases and a proposed mechanism. Br J Dermatol 2009;160:1322–6. PubMed

Roe N, Twilla JD, Duhart B, et al. Breast cancer patient with everolimus-induced angioedema: a rare occurrence with potential for serious consequences. J Oncol Pharm Pract 2017;23:318–20. PubMed